Entera Bio Ltd. (NASDAQ:ENTX) Stock Has Average Price Target of $9.60 According to Brokerages

Shares of Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $9.60.

A number of research analysts have recently commented on the company. Leerink Partners started coverage on Entera Bio in a report on Friday, September 18th. They set an “outperform” rating and a $9.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Entera Bio in a report on Tuesday, September 22nd. They issued an “overweight” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, October 15th. Wall Street Zen lowered shares of Entera Bio from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Finally, Guggenheim started coverage on shares of Entera Bio in a research report on Thursday, September 24th. They issued a “buy” rating and a $11.00 target price for the company.

Read Our Latest Research Report on ENTX

Entera Bio Price Performance

Shares of Entera Bio stock opened at $3.00 on Friday. The business’s fifty day moving average price is $2.90 and its two-hundred day moving average price is $2.01. The company has a market capitalization of $522.42 million, a P/E ratio of -7.69 and a beta of 1.48. Entera Bio has a 1-year low of $0.91 and a 1-year high of $4.20.

Entera Bio (NASDAQ:ENTX – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). On average, research analysts expect that Entera Bio will post -0.40 earnings per share for the current fiscal year.

Institutional Trading of Entera Bio

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its holdings in shares of Entera Bio by 338.4% in the first quarter. Renaissance Technologies LLC now owns 473,442 shares of the company’s stock valued at $526,000 after acquiring an additional 365,441 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Entera Bio during the third quarter valued at approximately $613,000. RA Capital Management L.P. bought a new stake in Entera Bio during the third quarter worth approximately $14,265,000. Nantahala Capital Management LLC bought a new stake in Entera Bio during the third quarter worth approximately $8,744,000. Finally, Seven Fleet Capital Management LP raised its holdings in Entera Bio by 51.9% during the first quarter. Seven Fleet Capital Management LP now owns 205,542 shares of the company’s stock worth $228,000 after purchasing an additional 70,224 shares in the last quarter. 14.11% of the stock is owned by institutional investors and hedge funds.

About Entera Bio

(Get Free Report)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company’s development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.

See Also

Analyst Recommendations for Entera Bio (NASDAQ:ENTX)

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.